BHVN logo

Biohaven Ltd.


BHVN: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.


Show BHVN Financials

Consumer Interest
SEC Filings

Recent trades of BHVN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by BHVN's directors and management

Government lobbying spending instances

  • $60,000 Jul 20, 2023 Issue: Health Issues
  • $50,000 Apr 20, 2023 Issue: Health Issues
  • $20,000 Jan 20, 2023 Issue: Health Issues
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of BHVN in WallStreetBets Daily Discussion


Recent insights relating to BHVN

CNBC Recommendations

Recent picks made for BHVN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BHVN

Corporate Flights

Flights by private jets registered to BHVN